Notably, some PET(Positron emission tomography) tracers, such as 18F-PEG6-IPQA [12, 13], 11C-erlotinib, 11C-PD153035 and 11C-gefitinib [14–16], and some antibodies [17], have been synthesized and used to evaluate the mutation status of EGFR in NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.